Introduction
============

Leri--Weill dyschondrosteosis (LWD) is caused by haploinsufficiency of SHOX in 60--70% of cases (intragenic deletions, duplications or mutations), and in 15--31% of patients without an intragenic mutation or deletion a putative enhancer sequence in the 3'-flanking region has been demonstrated ([@ref-2]; [@ref-8]). *SHOX* is located on the short arm of the X-chromosome in the pseudoautosomal (PAR) 1 region, thereby escaping X-inactivation, leading to a pseudoautosomal pattern of inheritance for LWD ([@ref-1]; [@ref-18]). So far, 7 enhancer sequences, 3 upstream and 4 downstream of *SHOX*, have been described ([@ref-11]; [@ref-16]; [@ref-9]; [@ref-13]; [@ref-3]; [@ref-4]). Deletion of one or more of the downstream enhancer sequences results in SHOX haploinsufficiency and LWD. [@ref-2] as well as [@ref-8] described a cohort of patients with different deletions in the downstream enhancer region, where various deletion sizes all resulted in LWD or idiopathic short stature. A deletion in the enhancer region upstream of *SHOX* has only recently been reported in one female patient and her father with idiopathic short stature ([@ref-3]), where two of the three upstream enhancer sequences were deleted.

LWD caused by a heterozygous mutation or deletion of *SHOX* is characterized by short stature, mesomelia, and Madelung deformity. Penetrance of the phenotype appears to be incomplete within families ([@ref-14]; [@ref-6]) and Madelung deformity and short stature tend to be more common and severe in females than in males ([@ref-6]). Mean height of index cases has been reported as −2.2 SDS ([@ref-6]; [@ref-15]) and height of affected mothers and fathers as −2.1 SDS and −1.6 SDS, respectively ([@ref-15]).

There is limited information about the phenotype of patients with a deletion in the enhancer region downstream of *SHOX*. However, from the available reports the phenotypic characteristics do not seem to differ much from those of patients with *SHOX* deletions or mutations ([@ref-2]; [@ref-17]; [@ref-15]).

Recently, a relatively small deletion of PAR1 was found by [@ref-7] in a father and son, of whom the son had short stature (−2.0 SDS), while the father did not (−0.44 SDS). Comparable deletions were already demonstrated by [@ref-8], but their exact size was not determined in detail. Subsequently this deletion was described in 30 unrelated families with LWD or ISS by [@ref-4] equivalent to 15.3% of probands with LWD and 1.9% of probands with idiopathic short stature, uncovering a novel downstream enhancer. The clinical phenotype of these patients showed a wide variability with height SDS ranging from −0.14 to −4.68.

We aimed at investigating the frequency of the various deletions in the 3'-flanking *SHOX* region and the possible phenotypic differences between patients with different sizes of deletions in this region.

Methods
=======

Clinical characteristics
------------------------

In 49 DNA samples sent to the Laboratory for Diagnostic Genome Analysis of the Department of Clinical Genetics (Leiden University Medical Center, Leiden) and in six of the DNA samples sent to the Section Genome Diagnostics of the Department of Genetics (University Medical Center Groningen, Groningen), for the determination of *SHOX* defects between 2005 and 2011, we found a deletion in the downstream enhancer region of *SHOX* in 29 probands, and 26 of their relatives (total of 28 families). In the same period in the Laboratory for Diagnostic Genome Analysis of the Department of Clinical Genetics (Leiden University Medical Center, Leiden) we detected 43 deletions of the complete gene, 22 mutations (missense, nonsense, splice site or frameshift) and 5 duplications of *SHOX* in a total of 1045 patients.

With consent of the Medical Ethical Committee of the LUMC, clinical data were collected and anonymized for 44 of the 55 patients (23 index patients and 21 affected relatives from 23 families). Two of the remaining 11 patients were excluded from the analysis of clinical features, because they suffered from an additional disorder, which would probably influence their growth (a skeletal dysplasia of unknown type (inconsistent with LWD), and a deletion 22q11, respectively). For 9 patients no additional clinical data could be obtained.

Demographic and clinical data collected were sex, age, height standard deviation score (SDS), sitting height to height ratio SDS and presence of Madelung deformity. Height SDS and sitting height/height SDS were calculated based on Dutch nation-wide references ([@ref-10]). We chose not to collect all data needed to calculate the Rappold score ([@ref-14]), because of the limitations of this scoring system in clinical practice: arm span, and length and bowing of the forearm are seldom measured by clinicians, appearance of muscular build is not very often spontaneously mentioned in clinical records, and the use of body mass index gives a higher score for obese patients. Instead, we chose to collect data about the classical clinical triad of Leri--Weill dyschondrosteosis: height, sitting height to height ratio (SH/H) and presence of Madelung deformity.

Molecular analysis
------------------

DNA isolation from peripheral blood and sequence analysis of the *SHOX* coding region including intron--exon boundaries was performed using standard procedures (primer sequences available upon request). Deletions and duplications were detected using the MRC-Holland MLPA kit (Salsa P018-D1) according to the manufacturer's instructions.

Statistical analysis
--------------------

The *t*-test and Fisher exact test were used to test for an association of genotype (deletion including PAR1 probes L05099-L05101 or larger deletions) with height SDS, SH/H SDS, and the presence of a Madelung deformity. Differences between index patients and their relatives were determined, as well as the influence of the gender of the patient.

Results
=======

Of the 28 families, 19 had the recurrent 47543 bp (47.5 kb) deletion encompassing PAR1 probes L05099-L05101 described by [@ref-4], containing a *SHOX* enhancer sequence (ECR1/CNE7). The deletion was found in 19 index cases and 16 of their relatives. Nine families (10 index patients and 10 relatives) had a larger deletion varying from a deletion that includes PAR1 probes L05096-L05104 to a deletion including PAR1 probes L05098-L05103 ([Fig. 1](#fig-1){ref-type="fig"}).

![Schematic representation of the SHOX locus and the surrounding enhancer regions.\
Schematic representation of the SHOX locus and location of the 3'-flanking PAR1 probes of the P018-D1 MLPA kit (MRC Holland). Extent of the deletions (blue bars) and the number of families (n) is indicated with the number of affected individuals between brackets. The SHOX gene is indicated with a purple box. The PAR1 probes are indicated with an \* and the four downstream enhancers (ECN4, ECN5, ECR1/CNE7 and CNE9) are indicated with green or red (the enhancer within the 47.5 deletion) triangles. The deletion described by Sabherwal includes PAR1 probes L05096-l L05101.](peerj-01-35-g001){#fig-1}

In the 44 individuals (23 families) of whom clinical information was available, mean height SDS was −1.9 (range −4.0 to 1.2) and SH/H SDS 1.5 (range −1.6 to 3.0). Madelung deformity was present in 19 of 33 patients. Mean height SDS and SH/H SDS in patients with the 47.5 kb deletions (*n* = 25) compared to patients with larger deletions (*n* = 19) are shown in [Fig. 2](#fig-2){ref-type="fig"}. Patients with the 47.5 kb deletion were on average 0.5 SD shorter than patients with larger deletions, but the difference did not reach statistical significance (*p* = 0.20). A comparison of the same clinical characteristics between the index patients and their affected relatives, and between male and female patients, is also shown in [Fig. 2](#fig-2){ref-type="fig"}. No significant differences were observed in the different subgroups of patients, as illustrated in [Figs. 2](#fig-2){ref-type="fig"} and [3](#fig-3){ref-type="fig"}. Presence or absence of a Madelung deformity in the subgroups of patients mentioned above is summarized in [Table 1](#table-1){ref-type="table"}. No significant differences were observed in any of the subgroups.

![Height (SDS) range in different subgroups of patients.\
Height (SDS) range in different subgroups of patients with a deletion in the downstream enhancer region of SHOX. del 47.5 kb = deletion that includes PAR1 probes L05099-L05101 in the downstream enhancer of SHOX; other del = larger deletion in the downstream enhancer of SHOX; ∗ = mean value; *n* = number of tested individuals; *p* = *p*-value measured by *t*-test.](peerj-01-35-g002){#fig-2}

![Sitting height to height ratio (SDS) range in different subgroups of patients.\
Sitting height to height ratio (SDS) range in different subgroups of patients with a deletion in the downstream enhancer region of SHOX. del 47.5 kb = deletion that includes PAR1 probes L05099-L05101 in the downstream enhancer of SHOX; other del = larger deletion in the downstream enhancer of SHOX; ∗ = mean value; *n* = number of tested individuals; *p* = *p*-value measured by *t*-test.](peerj-01-35-g003){#fig-3}
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###### Madelung deformity in different subgroups of patients with a deletion in the downstream enhancer region of SHOX.

Three comparisons are made in subgroups of patients. del 47.5 kb = deletion that includes PAR1 probes L05099-L05101 in the downstream enhancer of SHOX; other del = larger deletion in the downstream enhancer of SHOX.

![](peerj-01-35-g004)

                                         Madelung present   Madelung absent   *p*-value (Fisher exact test)
  -------------------------------------- ------------------ ----------------- -------------------------------
  Patients with del 47.5 kb (*n* = 17)   11                 6                 0.49
  Patients with other del (*n* = 16)     8                  8                 
  Index patients (*n* = 19)              10                 9                 0.72
  Relatives (*n* = 14)                   9                  5                 
  Male patients (*n* = 12)               7                  5                 0.72
  Female patients (*n* = 21)             14                 7                 

Discussion
==========

We show that the recently reported recurrent 47543 bp (47.5 kb) deletion ([@ref-4]) could also be demonstrated in 19 out of 28 Dutch families (68%) with a downstream deletion and has a similar clinical phenotype as larger deletions in the downstream region of *SHOX*. Height SDS, SH/H SDS and the presence of Madelung deformity all showed a large variation, regardless of deletion size, gender of the patient or whether the patient was an index patient or relative.

We have now shown that these deletions comprise an important part of our patient cohort. The lack of previous reports on this deletion could be due to doubt about the pathogenity of the deletion, because it is not overlapping the formerly described critical region in the enhancer region ([@ref-2]). However, recently the same research group convincingly reported this deletion to include a previously uncharacterized *SHOX* enhancer (ECR1/CNE7), proving the deletion to be pathogenic ([@ref-4]).

The average height SDS in our index cases (−2.2 SDS) is similar to mean height SDS in cohorts of patients with *SHOX* deletions and mutations ([@ref-6]). In the first report on patients with a deletion in the enhancer region [@ref-2] demonstrated 12 families with short stature and/or Madelung deformity with variable severity, with a height SDS ranging from −4.6 SD to 0.85 SD. [@ref-15] recently reported a mean height in their patients with a deletion encompassing *SHOX* of −2.3 SDS, while in the same study a mean height of −2.2 SDS was seen in patients with any deletion in the downstream region. In a smaller sample of patients with a deletion downstream of *SHOX* in the study of [@ref-17] a mean height SDS of −1.4 SDS was demonstrated. The results of these reports are in accordance with our observations, although in the two last mentioned reports it is suggested that the phenotype in patients with a deletion in the downstream enhancer region seems to be milder than in patients with a *SHOX* mutation or deletion. The six patients described by [@ref-17] with anomalies downstream of *SHOX* had a less severe short stature (height SDS −1.4) than those with other gene anomalies (height SDS −2.5; *n* = 16). Due to the small size of their sample they were not able to draw firm conclusions. [@ref-15] reported a higher percentage of idiopathic short stature (instead of LWD) in patients with a deletion in the downstream enhancer region interval compared to patients with a *SHOX* mutation or deletion, suggesting a milder phenotype in patients with a downstream deletion. However, classification of patient groups in this study shows some shortcomings, as also acknowledged by the authors, and comparisons must be taken with caution. Furthermore in contrast to the findings of [@ref-15]; [@ref-8] reported a higher percentage of downstream deletions in LWD patients compared to patients with idiopathic short stature. Therefore, genotype--phenotype correlations do not seem obvious.

Comparing all index patients with their relatives shows that mean height SDS is slightly higher in relatives, although not significantly different (*p* = 0.08), probably due to referral bias. Differences between male and female patients were not observed in our study, contrary to what is known about patients with *SHOX* deletions or mutations where females tend to present with a more severe phenotype than males ([@ref-6]). However, further confirmation is needed on a larger patient cohort.

The large variability of the phenotype confirms the findings in previous reports on patients with a deletion in the enhancer region 3' of *SHOX* ([@ref-2]; [@ref-8]; [@ref-12]; [@ref-17]; [@ref-15]). Not all index patients had short stature, which was also noticed in the study by [@ref-17], and has been observed in previous studies ([@ref-5]; [@ref-14]). Looking in detail at this group of eight patients with a height at last examination above −2 SDS, reason for a diagnostic *SHOX* analysis was the presence of Madelung deformity in five of them, and disproportion in combination with familial disproportionate short stature in one patient. Another patient had a recent height measurement of −1.4 SDS, but former height measurements were always around −2 SD, while several family members had disproportionate short stature. The last patient had a height in the normal range, but below her target height range. So, short stature is not always the leading clinical sign to request *SHOX* analysis, and referring clinicians do take into account other clinical characteristics of the patient and their relatives. The variability of the clinical phenotype is not limited to deletions of the enhancer region. Also for LWD caused by *SHOX* mutations or deletions, the phenotype has been described as highly variable ([@ref-6]). Thus, penetrance of the phenotype appears to be incomplete, even within families.

In conclusion, the phenotype in patients with a deletion in the downstream enhancer region of *SHOX* seems comparable to that of patients with a *SHOX* mutation or deletion, and the variability of the phenotype in the whole group of patients with a deletion in the enhancer region is remarkable. The recurrent 47.5 kb deletion downstream of *SHOX* leads to a phenotype comparable to that of larger deletions in the same region. Our data support that the 47.5 kb deletion is a pathogenic deletion, and therefore it seems plausible that an important enhancer region is located within the deletion interval.
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